To accelerate clinical development of its best-in-class and first-in- class immuno-oncology programs
Strasbourg, France – Montreal, Canada - May 10, 2022 – Domain Therapeutics, a biopharmaceutical company specializing in the research and development of innovative drugs targeting G Protein-Coupled Receptors (GPCRs) in immuno-oncology, announced today the closing of a US $42m (€39m) series A financing round co-led by Panacea Venture, CTI Life Sciences and 3B Future Health Fund, and joined by adMare BioInnovations, Schroders Capital, Omnes, Turenne Capital, Theodorus, Viva BioInnovator and existing investor Seventure Partners.
This investment is a significant step forward for the French-Canadian company as it seeks to bring novel therapeutic solutions to cancer patients, aimed at bypassing immunosuppression mediated by GPCRs. Domain Therapeutics will use the proceeds of this financing to i) conduct the clinical development of its EP4R antagonist, DT-9081, ii) advance two additional GPCR programs, including an anti- CCR8 antibody, to the Investigational New Drug application stage, and iii) progress its discovery-stage pipeline of a number of first-in-class assets targeting GPCRs, identified through its proprietary platforms.
“We are pleased to welcome our new shareholders and I thank them all for their commitment at this decisive stage of our company’s growth,” comments Pascal Neuville, CEO of Domain Therapeutics. “After having delivered a first GPCR drug candidate for immuno-oncology together with Merck KGaA, Domain is now committed to advance its own treatments reviving the immune system to defeat cancer.”
With the expansion of immune checkpoint inhibitor treatments and the understanding of how tumors highjack and escape the immune system, even under immunostimulating treatments, GPCRs have recently emerged as strategic targets responsible of immunosuppression and treatment-resistance mechanisms. Domain Therapeutics is leveraging its insights into GPCR science and technology to develop a robust immuno-oncology pipeline designed to harness the power of immunity and to broaden the impact of immunotherapies. In addition, Domain Therapeutics scientists are hunting for biomarkers, tissue microarray data, genetic mutations and protein expression to select patients who will benefit most from its immunotherapy treatments.
About Domain Therapeutics
Domain Therapeutics, a biopharmaceutical company operating in France and Canada, is dedicated to the discovery and development of new drug candidates targeting G Protein-Coupled Receptors (GPCRs), one of the most important classes of drug targets. The company focuses on developing high-value drug candidates to tackle GPCR-mediated immunosuppression in immune-oncology. www.domaintherapeutics.com
About Viva BioInnovator
As the investment division of Viva Biotech, Viva BioInnovator is dedicated to investing globally in biotech innovation with novel solutions to unmet medical needs across multiple therapeutic areas, ranging from biopharmaceuticals to devices, diagnostics, and life science tools. By leveraging Viva Biotech's deep experience and technical advantages in novel drug R&D, Viva BioInnovator provides both cash and in-kind services, also called Equity-for-Services (EFS), for its investments. www.vivabioinnovator.com